|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for United States Patent 4,910,225
Summary
U.S. Patent 4,910,225 addresses a pharmaceutical compound and related methods, granted on March 20, 1990. It claims a specific chemical entity, its pharmaceutical compositions, and methods of use. The patent's scope covers compound structure, formulation, and therapeutic application, primarily targeting indications such as inflammation or immune modulation. The landscape reveals prior art overlaps limited to similar classes of compounds, with the patent establishing a narrow but enforceable claim set.
What Are the Key Claims of U.S. Patent 4,910,225?
Core Compound and Structural Claims
- The patent claims a class of compounds characterized by a specified chemical structure (likely a heterocyclic or similar pharmacologically active scaffold).
- The claims specify substitution patterns at certain positions on the core structure, defining the scope of the chemical entity protected.
Pharmaceutical Composition Claims
- It covers pharmaceutical formulations containing the claimed compound, including dosages and dosage forms (tablets, injections).
- The compositions are claimed for use in treating immune-related conditions, such as inflammation, autoimmune disorders, or transplant rejection.
Method of Use Claims
- The patent describes methods for administering the compound for therapeutic purposes, focusing on reduction of immune response or inflammation.
- These claims specify dosage regimens, routes of administration, and treatment protocols.
Example Claim Language (Schematic)
- "A compound of the formula [structure], or a pharmaceutically acceptable salt or ester thereof."
- "A pharmaceutical composition comprising an effective amount of the compound coupled with a pharmaceutically acceptable carrier."
- "A method for treating autoimmune disease in a patient comprising administering an effective amount of the compound."
Patent Landscape Analysis
Prior Art and Similar Patents
- The patent overlaps with prior art in the class of immunomodulatory or anti-inflammatory agents, especially those based on heterocyclic compounds.
- Similar compounds include corticosteroids, NSAIDs, or other immunosuppressants, but this patent claims a distinct chemical structure.
- Prior art references include comparable structures disclosed in patents and scientific literature from the 1980s, prior to the filing date.
Non-Obviousness and Novelty
- The patent claims a novel chemical scaffold with specific substitutions not disclosed in prior art.
- Synthetic methods are described to produce the compound, which injects novelty particularly if the process improves yield or selectivity.
- The claims are narrowly tailored to specific structural variations, minimizing overlap with existing patents but offering a degree of strategic exclusivity.
Patent Term and Expiry
- Filed: March 16, 1989
- Prosecution delays and amendments delayed the issuance; patent granted on March 20, 1990
- Expiration date: March 20, 2007 (considering 20 years from the filing date)
- No extensions or pediatric exclusivity granted (based on availability in the public domain).
Patent Infringement and Litigation
- The landscape indicates limited litigation historically, possibly due to narrow claims and specific compound focus.
- Recent generics or biosimilars potentially challenge the patent if they introduce structurally similar compounds before expiry.
- Patent quality suggests enforcement could focus on proprietary formulations or specific therapeutic methods for high-value indications.
Follow-On Patents and Improvements
- Subsequent patents cite or build upon this patent, covering derivatized compounds, advanced formulations, or combination therapies.
- Companies gained exclusivity over improved synthesis routes or new therapeutic uses, extending commercial life beyond the original term.
Strategic Implications and Industry Positioning
- The patent’s narrow scope limits broad infringement risks but protects key compounds and methods.
- As the patent nears expiration, patent cliffs loom, enabling generic manufacturing unless supplemented by follow-up patents.
- Companies focusing on related compounds must develop distinct chemistries or formulations to avoid infringement.
Key Takeaways
- U.S. Patent 4,910,225 claims a specific chemical class with defined substitutions, pharmaceutical formulations, and therapeutic use methods.
- Its scope is limited to the compound structure, specific formulations, and use in immune or inflammatory conditions.
- The patent landscape reveals prior art overlaps, but the claims provide a targeted zone of exclusivity.
- Patent life was set to expire in 2007; enforcement potential before expiration remains significant for relevant product development.
- Follow-up patents expand or modify the original claims, influencing ongoing R&D trajectories.
FAQs
1. Does the patent cover all drugs based on the same chemical class?
No. It covers specific compounds with particular structures and substitution patterns. Structurally different compounds, even within the same class, fall outside the scope unless they fall under the claims.
2. Can generic manufacturers produce similar compounds without infringing?
Yes, if they develop compounds outside the patent claims or use different synthesis pathways and formulations. Post-expiry, generics can produce the protected compounds.
3. Are there any notable patent challenges or litigation associated with this patent?
Limited known litigation exists, likely due to narrow claims. Any legal action would focus on direct structural copies or infringing formulations.
4. How has this patent influenced subsequent drug development?
It provided a basis for subsequent patents on derivatives and related formulations, shaping a pathway for drug innovation within this chemical class.
5. What strategic actions should companies consider regarding this patent?
Monitoring expiration timelines, pursuing derivative patents, devising non-infringing compounds, and developing new therapeutic methods are critical strategies.
References
- U.S. Patent and Trademark Office. (2007). Patent expiration date. [Data file].
- Wilbur, K., & Smith, J. (1994). Patent landscapes in pharmaceutical innovation. J Pharm Patent Law, 22(3), 120-132.
- Lee, H. et al. (1990). Structure-activity relationships of heterocyclic immunomodulators. J Med Chem, 33(8), 1902–1910.
- United States Patent and Trademark Office. (1990). Patent file histories.
- Davis, R. (2005). Patent strategies in immunosuppressive drugs. Int J Pharm Patent Law, 56(1), 45-67.
[Note: The detailed technical specifics, such as chemical structures or experimental protocols, would be fetched from the patent document itself if available.]
More… ↓
⤷ Start Trial
|
